最新观点
Insights From Our Experts
Articles
Key Trends in Global Product Launch
The pharmaceutical industry continues to face a multitude of changes that have the potential to directly impact launch strategy. From more recent tangible trends like a rise in cost-containment policies, to ongoing net price transparency forces…
Navigating the Evolving Landscape of Internet Healthcare in China: Development Status, Challenges, and Future Prospects
Authors: Robin Arnold, Executive Vice President; Renyang Liu, Engagement Manager; Erica Wang, Associate Consultant Background Internet healthcare means using the internet to provide health and medical services. China has implemented “Internet Plus Healthcare” as a national…
VOICE OF THE CUSTOMER: Payer Pharmacy Directors Report ‘Back-to-Basics’ Contracting, Product Updates, and Pipeline Forecasts Drive Pharma Company Perceptions
Noticeable improvements in several relationship competencies separate the top companies from the rest of the industry. Post-pandemic industry dynamics have forced a shift in the way pharmaceutical companies call on their managed care customers. This past…
Unveiling the Future: AI Opportunities in FDA Compliance, Insights from the OPQ Symposium
In the dynamic realm of pharmaceuticals, staying ahead of the curve is not just an advantage; it’s a necessity. Recently, our team had the privilege of attending the CDER’s Office of Pharmaceutical Quality (OPQ) symposium, where…
‘Pharmatizing’ AI in Pharma
Amazon Web Services and EVERSANA are partners at the epicenter of transforming life sciences commercialization through technology solutions including AI. Experts Scott Snyder, Chief Digital Officer, EVERSANA, and Dr. Shakthi Kumar, Worldwide Head, Healthcare and Life…
Driving Patient-First Affordability in Seconds – Not Days: Accelerating Time to Therapy
Fewer than 60% of Pharmacy Benefit Manager (PBM) electronic benefit verifications (eBVs) accurately assess patients’ financial responsibilities, largely due to the industry’s reliance on AI algorithms for estimations. This leads to financial barriers for patients, hesitancy…
Adapting to Change: Examining the Implications of New EU Regulations on Commercialisation from the Perspectives of Patients, Providers, and Pharma Companies
In April, the European Federation of Pharmaceutical Industries and Associations’ (EFPIA) 2022 Patient W.A.I.T Indicator found that the average rate of availability for pharmaceuticals in Europe is 45%, down 2% on the previous year. Additionally, the…
Making Primary Market Research SMARTER Through Social Listening
Discover how EVERSANA is transforming the landscape of primary market research in the pharmaceutical industry through our unique approach to social listening. This insightful article from our APAC team highlights the common challenges faced by pharma…
Utilization of Indirect Treatment Comparison (ITC), External Control Arms (ECA) and Patient-Reported Outcome Measures (PROMs)
Health Technology Assessment (HTA) is crucial to assessing the effectiveness, safety and cost-effectiveness of healthcare interventions. Indirect Treatment Comparison (ITC) is one trend that has gained traction in the HTA space as a way to evaluate…
Lead Time Is All You Need: Patient Identification for Cell and Gene Therapies Using Machine Learning and Advanced Data Analytics
Discover how EVERSANA’s cutting-edge approach is revolutionizing patient identification for cell and gene therapies. In our white paper, “Lead Time Is All You Need: Patient Identification for Cell and Gene Therapies Using Machine Learning and Advanced…